The trials are expected to take 2 years and they then have to register in China (who knows what the Australia-China relationship will look like then). So I would not expect any revenue until FY24 assuming it all works out. The market is forward looking, but not out to FY24 on trials and registration that might not work out. I'm giving no value to this in my valuation.
Ann: ENTERS JV - IN VITRO DIAGNOSTIC BLOOD BANK REAGENTS IN CHINA, page-11
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PGC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.010(2.33%) |
Mkt cap ! $695.2M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 42.5¢ | 41.0¢ | $1.013M | 2.435M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200000 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 54906 | 2 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PGC (ASX) Chart |